Forbes magazine recently reported on the pharmaceutical industry’s very successful 2005. Lat year, U.S. prescription drug sales grew 5.4 percent to $251.8 billion, compared with $238.9 billion in sales the previous year. The volume of total U.S. dispensed prescriptions was up significantly over 2004, growing 4.7 percent after adjusting for longer-duration mail order prescriptions.
Generics, traditionally a volatile segment of the pharmaceutical market, posted strong sales growth last year of 20.6 percent. Growth was driven by the continued ramp-up of the 2004 generic launches of gabapentin, oxycodone HCl ER, bupropion HCl SR and quinapril HCl, and 2005 generic introductions of azithromycin, fexofenadine and transdermal fentanyl.
Lipitor remains the most prescribed drug in 2005, followed by HYCD/APAP, Norvasc, Toprol-XL and Synthroid.
All of this data comes from IMS Health, an information and research firm that also follows the retail drug industry.